Why Albumin Infusion Doesn't Always Raise Albumin Levels

 

Why Albumin Infusion Doesn't Always Raise Albumin Levels: Understanding Distribution and Leakage in Critical Illness

Dr Neeraj Manikath , claude.ai

Abstract

Albumin infusion is commonly administered in critically ill patients for volume resuscitation, correction of hypoalbuminemia, and specific clinical indications. However, clinicians frequently observe that serum albumin concentrations fail to increase proportionally or may not rise at all following albumin administration. This phenomenon, often perplexing to trainees and experienced clinicians alike, reflects fundamental alterations in albumin kinetics during critical illness. This review elucidates the mechanisms underlying albumin distribution, transcapillary escape, and degradation in health and disease, providing a framework for understanding why albumin infusion may not achieve expected increments in serum levels. We discuss the pathophysiology of capillary leak, altered volume of distribution, accelerated catabolism, and ongoing losses that characterize critical illness, and provide practical guidance for appropriate albumin use and monitoring.

Keywords: Albumin, capillary leak syndrome, fluid resuscitation, hypoalbuminemia, transcapillary escape rate, volume of distribution

---

Introduction

Serum albumin, the most abundant plasma protein synthesized exclusively by hepatocytes, serves multiple physiological roles including maintenance of oncotic pressure, drug and hormone transport, antioxidant functions, and modulation of vascular permeability.¹ In critically ill patients, hypoalbuminemia is nearly universal, affecting 30-70% of ICU admissions, and is associated with increased morbidity and mortality.²,³

Despite the intuitive appeal of correcting hypoalbuminemia through exogenous albumin administration, clinicians frequently encounter a frustrating clinical scenario: following albumin infusion, the measured serum albumin level shows minimal or no increase, or rises transiently only to rapidly decline. Understanding this phenomenon requires appreciation of albumin's complex pharmacokinetics and the profound alterations in vascular permeability and body fluid compartments that characterize critical illness.

Normal Albumin Physiology and Distribution

Synthesis and Pool Distribution

Healthy hepatocytes synthesize approximately 12-15 grams of albumin daily, with synthesis rates regulated by oncotic pressure, nutritional status, and inflammatory mediators.⁴ The total body albumin pool in a 70-kg adult averages 300-350 grams, distributed between intravascular (120-140g, 40%) and extravascular (180-210g, 60%) compartments.⁵ This distribution is not static but dynamic, with continuous bidirectional flux across the capillary membrane.

Transcapillary Escape Rate (TER)

The transcapillary escape rate, defined as the fraction of intravascular albumin that leaves the vascular space per unit time, normally ranges from 4-6% per hour in healthy individuals.⁶ This translates to approximately 5-10 grams of albumin crossing from the intravascular to the extravascular space hourly, with an equivalent amount returning via lymphatic drainage. The net result is a half-life of intravascular albumin of 12-16 hours under normal conditions, though total body albumin half-life is approximately 19-21 days.⁷

The Glycocalyx and Endothelial Barrier

The endothelial glycocalyx—a delicate layer of proteoglycans, glycoproteins, and glycosaminoglycans lining the luminal surface of endothelium—serves as the primary barrier to albumin extravasation.⁸ This structure, typically 0.5-1.0 μm thick, contributes more to reflection of albumin than the endothelial cells themselves. Damage to the glycocalyx dramatically increases vascular permeability to macromolecules.⁹

---

Pathophysiology in Critical Illness

Capillary Leak Syndrome

Critical illness triggers a systemic inflammatory response characterized by endothelial activation, glycocalyx degradation, and increased vascular permeability—collectively termed "capillary leak syndrome."¹⁰ Multiple mechanisms contribute:

1. Inflammatory Mediator Release Cytokines (TNF-α, IL-1β, IL-6), complement activation products, and damage-associated molecular patterns (DAMPs) directly increase endothelial permeability through:

• Disruption of intercellular tight junctions (VE-cadherin, occludin)¹¹
• Actin cytoskeleton reorganization creating paracellular gaps
• Upregulation of transcellular vesicular transport¹²

2. Glycocalyx Degradation Sepsis, ischemia-reperfusion injury, and hypervolemia cause enzymatic degradation (matrix metalloproteinases, heparanase) and mechanical shedding of the glycocalyx.¹³ Circulating syndecan-1 levels—a marker of glycocalyx damage—correlate with capillary leak severity and mortality.¹⁴

3. Altered Capillary Hydrostatic and Oncotic Forces The classical Starling equation has been revised to emphasize the importance of the subglycocalyx space rather than interstitial oncotic pressure in determining fluid filtration.¹⁵ When the glycocalyx is degraded, the reflection coefficient for albumin (σ) decreases from ~0.95 to 0.5-0.7, meaning albumin no longer effectively retains fluid in the vascular space.¹⁶

Increased Transcapillary Escape Rate

In critical illness, TER can increase to 10-30% per hour or even higher in severe septic shock.¹⁷,¹⁸ This means:

• Infused albumin rapidly redistributes from intravascular to extravascular spaces
• The effective intravascular half-life decreases from 12-16 hours to as little as 2-4 hours
• Administered albumin may transiently increase plasma levels but quickly equilibrates with the expanded interstitial space

Expanded Volume of Distribution

Critical illness expands the extravascular albumin pool through:

• Increased interstitial fluid volume: Aggressive fluid resuscitation, capillary leak, and decreased lymphatic clearance expand the interstitial space to 200-400% of normal.¹⁹
• Third-space accumulation: Peritoneal, pleural, and bowel wall edema further sequesters albumin outside the circulation.²⁰
• Decreased reflection coefficient: Lower σ values allow greater albumin extravasation with each pass through capillary beds.

Clinical Pearl: In a patient with severe septic shock who has received 8 liters of crystalloid, the extravascular space may expand to accommodate 250-300 grams of albumin (versus 180g normally), with only 80-100 grams remaining intravascular despite this massive pool.

Accelerated Catabolism and Decreased Synthesis

Increased Degradation Albumin catabolism increases in critical illness through:

• Uptake by activated macrophages and degradation in lysosomes²¹
• Increased renal tubular reabsorption and catabolism (in proteinuric states)
• Loss via extracorporeal circuits, wounds, drains, and gastrointestinal tract²²

Studies using labeled albumin demonstrate that fractional catabolic rate increases from 6-8% to 15-20% daily in severe sepsis.²³

Impaired Synthesis Paradoxically, hepatic albumin synthesis often decreases in critical illness despite hypoalbuminemia:

• Inflammatory cytokines (especially IL-6) suppress albumin gene transcription while upregulating acute-phase proteins²⁴
• Hepatic hypoperfusion and dysfunction reduce synthetic capacity
• Malnutrition and negative nitrogen balance limit substrate availability²⁵

This creates a "negative feedback loop": hypoalbuminemia, which normally stimulates synthesis, cannot overcome inflammatory suppression.

Ongoing Pathological Losses

Critically ill patients experience albumin losses through multiple routes:

• Renal: Proteinuria (septic AKI, ATN) may cause 5-20g albumin loss daily²⁶
• Gastrointestinal: Protein-losing enteropathy, diarrhea, fistulae
• Skin: Burns (up to 50g/day), wounds, necrotizing soft tissue infections²⁷
• Extracorporeal: Continuous renal replacement therapy (CRRT) removes 10-15g albumin daily²⁸
• Drains and ascites: Large-volume paracentesis, chest tubes, surgical drains

Clinical Hack: In a patient receiving CRRT with significant proteinuria and surgical drains, albumin losses may exceed 30-40 grams daily—equivalent to 3-4 vials of 25% albumin—before considering any administered albumin that leaks into extravascular spaces.

---

Quantifying the Problem: Mathematical Models

Expected vs. Observed Albumin Increment

A simplified calculation for expected albumin rise following infusion:

Expected Δ Albumin (g/dL) = (Albumin dose in grams) / (Plasma volume in dL × 2)

The multiplication by 2 accounts for distribution into extravascular space over 24 hours in normal physiology.²⁹

Example: A 70-kg patient with plasma volume ~3L (30 dL) receives 25g albumin:

• Expected rise: 25g / (30 dL × 2) = 0.42 g/dL
• Observed rise in health: ~0.3-0.4 g/dL at 24 hours
• Observed rise in septic shock: 0-0.15 g/dL or even negative

The Leak Equation

A more sophisticated model accounting for capillary leak:³⁰

Plasma Albumin Concentration = (Total Albumin Pool) × (Intravascular Fraction) / (Plasma Volume)

Where:

• Intravascular fraction decreases from 40% to 20-25% in severe capillary leak
• Total albumin pool includes infused albumin but is reduced by ongoing losses
• Plasma volume is often expanded by fluid resuscitation

This equation explains why even large albumin doses may not significantly raise plasma levels when leak is severe.

---

Clinical Scenarios: When and Why Albumin Levels Don't Rise

Scenario 1: Septic Shock with Massive Fluid Resuscitation

Clinical Vignette: A 68-year-old with septic shock from pneumonia receives 10L crystalloid and 100g albumin over 24 hours. Initial albumin 1.8 g/dL, post-infusion 1.9 g/dL.

Explanation:

• High TER (20-30%/hour) causes rapid albumin extravasation
• Expanded plasma volume (dilutional effect from 10L crystalloid)
• Glycocalyx destruction reduces albumin's oncotic effectiveness
• Expanded interstitial space (up to 15L excess) dilutes the total albumin pool
• Ongoing SIRS suppresses hepatic synthesis

Oyster: The failure of albumin to rise doesn't necessarily indicate "futility." The infused albumin may still provide benefit through expansion of interstitial oncotic pressure (reducing further fluid accumulation), antioxidant effects, and drug-binding capacity, even if plasma levels remain low.³¹

Scenario 2: Acute Respiratory Distress Syndrome (ARDS)

Pathophysiology: Increased pulmonary capillary permeability in ARDS allows albumin to leak into alveolar space, where it:

• Accumulates in pulmonary edema fluid (albumin concentration in edema fluid may reach 50-70% of plasma)³²
• Is not recovered by lymphatics due to impaired clearance
• May worsen oxygenation by impairing surfactant function³³

Clinical Pearl: In ARDS, rising pleural effusion protein or edema fluid protein concentrations despite stable or falling serum albumin indicates ongoing pulmonary capillary leak. This suggests albumin infusion will preferentially accumulate in the lungs rather than maintain plasma levels.

Scenario 3: Post-Cardiac Surgery/Cardiopulmonary Bypass

Mechanisms:

• Cardiopulmonary bypass causes systemic inflammatory response and glycocalyx shedding³⁴
• Hemodilution from pump prime expands plasma volume
• Hypothermia increases vascular permeability
• Surgical drains remove albumin-rich fluid
• TER increases 2-3 fold, peaking at 12-24 hours post-bypass³⁵

Clinical Hack: Wait 24-48 hours post-bypass before assessing albumin levels after infusion, as the acute inflammatory phase and maximal capillary leak occur early. Albumin given in the first 24 hours will largely extravasate; administration at 48-72 hours may be more effective.

Scenario 4: Cirrhosis with Sepsis

Complex Scenario:

• Baseline low albumin due to impaired synthesis
• Portal hypertension and splanchnic vasodilation expand distribution volume
• Sepsis superimposed on chronic liver disease causes severe capillary leak
• Ascites and peripheral edema sequester large albumin pools
• Paracentesis causes direct albumin loss³⁶

Evidence: The ATTIRE trial showed that targeted albumin supplementation (keeping levels >30 g/L) in decompensated cirrhosis did not improve survival despite successful maintenance of albumin levels in the treatment group.³⁷ This suggests that achieving target levels requires enormous doses when synthesis is impaired and distribution volume is expanded.

Scenario 5: Burns

Massive Capillary Leak:

• Thermal injury causes immediate and profound increase in capillary permeability
• TER may exceed 30-40% per hour in first 48 hours³⁸
• Albumin extravasation occurs both at burn site and systemically
• Evaporative losses from burn wounds compound albumin depletion
• Massive fluid resuscitation further expands interstitial space

Evidence-Based Approach: The Cochrane review found no mortality benefit for albumin in burns and potential harm with early administration, possibly because albumin accumulates in interstitial space, worsening edema.³⁹ Current practice favors crystalloid resuscitation initially, with albumin reserved for after 24 hours when capillary integrity begins to restore.

---

Measuring and Monitoring Albumin Kinetics

Biomarkers of Capillary Leak

1. Syndecan-1

• Glycocalyx component released during endothelial damage
• Levels >150 ng/mL predict severe capillary leak¹⁴
• Rising levels suggest ongoing endothelial injury despite therapy

2. Angiopoietin-2/Angiopoietin-1 Ratio

• Ratio >2 indicates endothelial activation and leak⁴⁰
• May guide timing of albumin administration

3. Extravascular Lung Water Index (EVLWI)

• Measured by transpulmonary thermodilution
• EVLWI >10 mL/kg suggests significant pulmonary capillary leak⁴¹
• Rising EVLWI despite negative fluid balance indicates ongoing albumin extravasation

Clinical Pearl: If available, measuring EVLWI before and after albumin bolus can help assess whether albumin remains intravascular or contributes to interstitial edema. An increase in EVLWI without corresponding hemodynamic improvement suggests futile administration.

Colloid Oncotic Pressure (COP)

While not routinely measured, COP provides functional assessment of albumin's oncotic effect:

• Normal COP: 25-28 mmHg
• Critical illness: Often 12-18 mmHg despite albumin infusion⁴²
• COP <15 mmHg associated with increased edema formation

Limitation: When reflection coefficient (σ) is markedly reduced (<0.7), COP gradients become less relevant as albumin freely crosses the capillary membrane, making COP measurements less clinically useful.⁴³

---

Evidence Base: Clinical Trials and Albumin Efficacy

SAFE Study (2004)

The landmark Saline versus Albumin Fluid Evaluation study randomized 6,997 ICU patients to 4% albumin or normal saline for fluid resuscitation.⁴⁴ Key findings:

• No difference in 28-day mortality (RR 0.99, 95% CI 0.91-1.09)
• Similar organ dysfunction and ICU length of stay
• Subgroup analysis: Possible harm in traumatic brain injury (TBI) patients (RR 1.63, p=0.003)

Why didn't albumin improve outcomes?

• Patients with capillary leak can't maintain intravascular albumin
• Albumin that extravasates provides no oncotic benefit
• Both crystalloid and colloid expand interstitial volume similarly when leak is present

ALBIOS Study (2014)

The Albumin Italian Outcome Sepsis trial randomized 1,818 severe sepsis patients to albumin plus crystalloid (maintaining albumin ≥30 g/L) versus crystalloid alone.⁴⁵

• No difference in 28-day or 90-day mortality
• Albumin group achieved target levels but required median 300g over 28 days
• Post-hoc analysis suggested benefit in septic shock subgroup

Interpretation: Even with aggressive supplementation maintaining target levels, albumin didn't improve survival, suggesting that correcting the number doesn't address the underlying pathophysiology.

RASP Trial (2024)

Recent trial of 20% albumin vs. crystalloid in septic shock with albumin <30 g/L showed no mortality difference but reduced fluid balance and faster shock resolution.⁴⁶ However, albumin levels in the treatment group rose modestly (from 24 to 28 g/L) despite substantial albumin administration, confirming the kinetic challenges described in this review.

---

Practical Approach: When to Give Albumin (Despite the Challenges)

Evidence-Based Indications

1. Large-Volume Paracentesis

• Indication: >5L ascites removal
• Dose: 6-8g per liter removed
• Evidence: Reduces post-paracentesis circulatory dysfunction⁴⁷
• Rationale: Rapid fluid shifts; albumin helps maintain effective circulating volume despite ongoing leak

2. Spontaneous Bacterial Peritonitis (SBP)

• Indication: SBP in cirrhosis, especially if creatinine >1 mg/dL or bilirubin >4 mg/dL
• Dose: 1.5 g/kg at diagnosis, 1 g/kg on day 3
• Evidence: Reduces mortality and renal impairment (NNT ~5)⁴⁸
• Rationale: Specific immunomodulatory and endothelial-protective effects beyond volume expansion

3. Hepatorenal Syndrome (HRS)

• Indication: Type 1 HRS
• Dose: 20-40g daily with vasoconstrictors
• Evidence: Improves renal recovery when combined with terlipressin or midodrine⁴⁹
• Mechanism: Reduces splanchnic vasodilation, improves effective circulating volume

4. Fluid Resuscitation in Septic Shock (Conditional)

• Consideration: After initial crystalloid (30 mL/kg), if persistent hypotension and tissue hypoperfusion
• Dose: 20-25% albumin boluses
• Evidence: Equipoise with crystalloid; may reduce cumulative fluid balance⁵⁰
• Rationale: Even if extravasates, may provide modest hemodynamic advantage during acute resuscitation

Situations Where Albumin Unlikely to Raise Levels

1. Active Severe Capillary Leak

• First 24-48 hours of septic shock, ARDS, burns
• Syndecan-1 >150-200 ng/mL
• Rising EVLWI despite negative fluid balance

Clinical Hack: If you must give albumin during active leak (e.g., refractory hypotension), give as continuous infusion (e.g., 25g over 4-6 hours) rather than rapid bolus. Rapid administration may transiently worsen pulmonary edema by overwhelming even partially intact endothelial barriers before extravasation occurs.⁵¹

2. Ongoing Massive Losses

• CRRT with high effluent rates (>35 mL/kg/hr)
• Large-volume drainage (>500 mL/day of protein-rich fluid)
• Entero-cutaneous fistulae with high output

Strategy: Accept lower albumin targets; address source of loss rather than trying to replace indefinitely.

3. Severe Synthetic Dysfunction

• Acute liver failure
• End-stage cirrhosis (MELD >30)
• Severe malnutrition without adequate protein intake

Reality: Exogenous albumin cannot overcome profound synthetic failure. Temporary rise will be brief as catabolism exceeds administration.

---

Optimizing Albumin Therapy: Practical Pearls

Timing Considerations

Early vs. Late Administration

• Early (<24 hours of shock): Maximal capillary leak, most extravasation, least intravascular retention
• Late (>48-72 hours): Endothelial recovery begins, improved retention, better hemodynamic effect⁵²

Clinical Pearl: In septic shock, if albumin is part of your resuscitation strategy, consider waiting 24-48 hours if the patient is stabilizing. You'll achieve better plasma level increases and potentially greater hemodynamic benefit with the same dose.

Concentration Matters

20% vs. 25% vs. 5% Albumin

• Hyperoncotic (20-25%): Draws fluid from interstitium into vessels (transiently)
  • Volume expansion 4-5× infused volume
  • Useful in volume-overloaded patients needing albumin
  • May temporarily worsen pulmonary edema if pulmonary capillary leak present⁵³
• Isooncotic (5%): Remains primarily intravascular initially
  • Volume expansion ~1× infused volume
  • Better for hypovolemic shock
  • Less risk of precipitating pulmonary edema

Hack: In a patient with ARDS who needs albumin (e.g., for SBP), use 5% rather than 25% to minimize risk of worsening pulmonary edema from transient fluid shifts before equilibration occurs.

Dosing Strategies

Bolus vs. Continuous Infusion

• Bolus: Traditional 25-100g over 30 minutes
  • Rapid hemodynamic effect
  • Potentially overwhelms damaged endothelium
  • Risk of transient pulmonary edema
• Continuous infusion: 25-50g over 4-6 hours or 100-200g over 24 hours
  • May allow better endothelial accommodation
  • Sustained oncotic support
  • Potentially less extravasation (theoretical; not proven)⁵⁴

Monitoring Response

Appropriate Endpoints (NOT just albumin level):

1. Hemodynamics: MAP, cardiac output, stroke volume variation
2. Perfusion: Lactate clearance, ScvO₂, capillary refill
3. Fluid balance: Cumulative balance, need for additional fluids
4. Organ function: Urine output, creatinine, liver enzymes

Clinical Oyster: Success shouldn't be measured by achieving a target albumin level but by clinical outcomes. A patient whose albumin rises from 1.8 to 2.5 g/dL but requires ongoing massive fluid resuscitation hasn't truly benefited. Conversely, a patient whose level stays at 2.0 g/dL but achieves shock reversal and net-even fluid balance may have benefited significantly.

---

Special Populations

Traumatic Brain Injury (TBI)

The SAFE-TBI Controversy Subgroup analysis showing increased mortality in TBI patients receiving albumin led to strong recommendations against its use.⁴⁴ Proposed mechanisms:

• Albumin extravasation through disrupted blood-brain barrier increases ICP
• Worsens cerebral edema
• No proven benefit in TBI; use crystalloid

Current Recommendation: Avoid albumin in TBI (Class III recommendation)⁵⁵

Acute Kidney Injury (AKI) and CRRT

Challenge: CRRT continuously removes albumin (sieving coefficient ~0.8-1.0 for high-flux membranes)²⁸

• Convective clearance: ~0.5-0.8 g/hour
• Daily loss: 12-18 grams with standard CRRT dosing

Clinical Approach:

• Accept lower albumin targets (>2.0 g/dL rather than >3.0 g/dL)
• Optimize nutrition to support endogenous synthesis
• Consider albumin supplementation only if level <2.0 g/dL AND another indication exists (e.g., refractory shock)
• Don't chase normal levels; you'll lose the battle against continuous removal

Pregnancy and Preeclampsia

Severe Preeclampsia Considerations:

• Massive capillary leak (especially pulmonary)
• Hypoalbuminemia common (1.5-2.5 g/dL)
• Risk of pulmonary edema very high⁵⁶

Approach:

• Avoid albumin for hypoalbuminemia alone
• Consider only if severe hypovolemia with refractory hypotension
• Aggressive diuresis post-delivery more important than albumin replacement
• Levels will spontaneously recover as capillary leak resolves postpartum

---

Alternatives and Adjuncts to Albumin

Other Colloids

Hydroxyethyl Starch (HES)

• DO NOT USE: Increased mortality, AKI, and need for RRT in sepsis (CHEST, 6S, CRYSTMAS trials)⁵⁷,⁵⁸
• Withdrawn or restricted in many countries

Gelatins

• Limited availability, potential allergic reactions
• No mortality benefit demonstrated
• Not recommended

Fresh Frozen Plasma (FFP)

• Contains albumin (~3g per unit) plus clotting factors
• Consider if coagulopathy present
• Not for volume expansion alone

Optimizing Endogenous Synthesis

Nutritional Support

• Adequate protein delivery: 1.2-2.0 g/kg/day (higher in burns, trauma)⁵⁹
• Branched-chain amino acid supplementation may enhance albumin synthesis⁶⁰
• Early enteral nutrition when feasible

Controlling Inflammation

• Source control (drain abscesses, remove infected hardware)
• Appropriate antibiotics
• Avoiding excessive fluid resuscitation (limiting capillary leak progression)⁶¹

Clinical Pearl: The most effective way to raise albumin levels in a critically ill patient is to resolve the underlying illness. Every day of persistent sepsis or SIRS costs 5-10 grams of albumin through accelerated catabolism and suppressed synthesis—more than you're likely to replace exogenously.

---

Economic Considerations

Cost-Effectiveness Analysis

Albumin Cost: Approximately $50-150 per 25g vial (varies by region and concentration)

• Maintaining albumin >30 g/L in sepsis may require 200-400g over 28 days
• Cost per patient: $400-2,400

ALBIOS Economic Analysis Despite no mortality benefit, albumin increased costs by approximately €600-900 per patient without improving quality-adjusted life years.⁶² This raises questions about routine use for hypoalbuminemia correction.

Value-Based Approach:

• Reserve for evidence-based indications (SBP, large-volume paracentesis, HRS)
• Avoid routine correction of low numbers in critically ill patients
• Consider societal resources when clinical benefit is marginal

---

Teaching Points: Pearls and Oysters

Pearls 💎

1. The 40/60 Rule: Normal albumin distribution is 40% intravascular, 60% extravascular. Any infused albumin will eventually equilibrate to this ratio—in critical illness, equilibration is faster and ratio may become 25/75.
2. The 24-Hour Window: Wait 24-48 hours after acute shock/injury before expecting albumin infusions to significantly raise plasma levels. Giving earlier isn't necessarily futile (may provide hemodynamic support), but don't expect the number to rise.
3. Leak doesn't mean lost: Albumin in the interstitium still provides oncotic pressure that may limit further fluid extravasation. A "failed" rise in plasma albumin doesn't mean the infusion was completely ineffective.
4. The Crystalloid Paradox: Aggressive crystalloid resuscitation (>5L in first 24 hours) worsens glycocalyx damage and capillary leak, making subsequent albumin infusions even less likely to raise plasma levels.⁶³
5. Syndecan-1 as a Guide: If available, syndecan-1 >150 ng/mL indicates severe glycocalyx damage—a sign that albumin infusion will likely extravasate rapidly.
6. CRRT Math: With typical CRRT settings (35 mL/kg/hr in a 70kg patient), you're removing ~15g albumin daily. You need 1-2 vials just to replace CRRT losses before addressing hypoalbuminemia.
7. The 72-Hour Recovery: In most cases of septic shock, endothelial recovery begins around 48-72 hours if source control is achieved. Albumin given after this point is more likely to remain intravascular.
8. Burns are Different: In major burns, the capillary leak is so profound in first 24-48 hours that albumin should be avoided. The Parkland formula (crystalloid-based) remains standard for early burn resuscitation.

Oysters 🦪

1. The Normal Level Illusion: A patient with albumin 3.5 g/dL on ICU day 7 is NOT normal—this level in a recovering critically ill patient represents significant expansion of total body albumin pool (possibly 400-500 grams vs. 300 grams normally), with most sequestered in expanded interstitial space.
2. The Negative Harm Signal: Multiple large trials (SAFE, ALBIOS, RASP) show albumin is SAFE—not inferior to crystalloid and not causing harm in most populations (except TBI). The failure to show benefit doesn't mean it's harmful when given for appropriate indications.
3. The Malnutrition Trap: Giving albumin to a malnourished patient with hypoalbuminemia due to poor intake (not inflammation) may suppress endogenous synthesis through negative feedback, ultimately worsening long-term nutritional recovery. Nutrition, not infusion, is the answer.⁶⁴
4. The Time-Concentration Dissociation: You may observe excellent hemodynamic response to albumin (increased MAP, decreased vasopressor requirement) despite zero increase in plasma albumin level. The hemodynamic effect can occur within minutes while redistribution takes hours—they're measuring different phenomena.
5. The Ascites Paradox: In cirrhosis, albumin infusion may worsen ascites formation despite raising plasma levels by increasing portal pressure and hydrostatic forces exceeding any oncotic benefit.⁶⁵ This is why albumin is recommended after paracentesis (removing fluid) but not for preventing ascites formation.

---

Future Directions

Novel Albumin Formulations

Recombinant Albumin

• May offer advantages in purity and consistency
• Potential for glycation or PEGylation to alter pharmacokinetics⁶⁶

Modified Albumin with Reduced Extravasation

• Conjugated albumin with larger molecular weight
• Increased affinity for endothelial receptors
• Currently experimental⁶⁷

Biomarkers for Patient Selection

Precision Medicine Approach:

• Use of syndecan-1, angiopoietin-2, or endothelial injury scores to identify patients most likely to benefit
• Avoid albumin in patients with severe leak; target those with moderate endothelial dysfunction⁶⁸

Combination Strategies

Albumin + Endothelial Protective Agents

• Sphingosine-1-phosphate pathway modulators
• Statins or prostacyclin analogs to reduce leak⁶⁹
• Early data suggest combinations may allow better albumin retention

Glycocalyx Restoration

• Sulodexide or heparin for glycocalyx repair
• Theoretical benefit of reducing leak before albumin administration⁷⁰
• Clinical trials needed

---

Conclusion

The failure of albumin infusion to consistently raise plasma albumin levels in critically ill patients reflects fundamental alterations in vascular permeability, fluid distribution, and protein kinetics rather than therapeutic futility. Understanding the mechanisms—increased transcapillary escape rate, expanded volume of distribution, accelerated catabolism, impaired synthesis, and ongoing losses—allows clinicians to set appropriate expectations and optimize albumin use.

Albumin should be viewed not primarily as a "correction" for low numbers but as a therapeutic agent for specific clinical indications where evidence supports its use: large-volume paracentesis, SBP, hepatorenal syndrome, and as one option (among several reasonable choices) for fluid resuscitation in septic shock. The goal is not to normalize albumin levels but to provide hemodynamic support, reduce

N

Continue

fluid requirements, and in specific cases (SBP, HRS), leverage albumin's unique immunomodulatory and endothelial-protective properties.

As we advance toward precision critical care, biomarkers of endothelial injury and capillary leak may help identify patients most likely to benefit from albumin therapy and those in whom administration will be futile. Until then, clinicians must recognize that a low albumin level in critical illness is primarily a marker of disease severity and inflammatory burden rather than a therapeutic target in itself.

The most effective strategy for raising albumin levels remains treating the underlying disease, achieving source control, providing adequate nutrition, and limiting iatrogenic factors that worsen capillary leak. When albumin is indicated, timing administration after the acute inflammatory phase (48-72 hours), using appropriate concentrations based on volume status, and monitoring clinical endpoints rather than laboratory values will optimize outcomes.

Final Pearl: When albumin levels don't rise after infusion, you haven't failed—you've encountered the predictable consequences of critical illness pathophysiology. The question isn't "Why didn't it work?" but rather "Did my patient benefit from the hemodynamic support, reduced fluid requirements, or specific indication for which I gave it?"

---

Key Clinical Messages for Postgraduate Trainees

What NOT to Do ❌

1. Don't chase albumin numbers in critically ill patients without specific indications
2. Don't give albumin in the first 24 hours of major burns expecting benefit
3. Don't use albumin in traumatic brain injury (associated with harm)
4. Don't expect proportional rises in serum albumin after infusion during active inflammation
5. Don't give repeated boluses when levels don't rise—this suggests severe leak where additional albumin will also extravasate
6. Don't use albumin as primary nutrition in malnourished patients
7. Don't use hydroxyethyl starch as an alternative (increases mortality and AKI)

What TO Do ✅

1. Do use albumin for evidence-based indications: SBP, large-volume paracentesis, HRS
2. Do consider timing: Wait 48-72 hours after acute shock if possible for better retention
3. Do monitor clinical endpoints: Hemodynamics, perfusion, fluid balance—not just albumin level
4. Do recognize capillary leak: Use biomarkers (syndecan-1) or clinical signs (EVLWI, third-spacing) to assess
5. Do calculate ongoing losses: CRRT, drains, proteinuria—these may exceed replacement capacity
6. Do optimize nutrition: 1.2-2.0 g/kg/day protein to support endogenous synthesis
7. Do treat the underlying disease: Source control and resolution of inflammation are more effective than exogenous replacement
8. Do use lower concentrations (5%) in ARDS to minimize pulmonary edema risk
9. Do accept lower targets in patients with ongoing massive losses (e.g., CRRT, high-output fistulae)

---

Case-Based Learning: Applying the Concepts

Case 1: The Confusing Septic Shock

Presentation: 55-year-old with perforated diverticulitis and fecal peritonitis. Taken to OR for washout and colostomy. Postoperatively develops septic shock requiring norepinephrine 0.3 mcg/kg/min. Albumin level 1.6 g/dL.

Resident's Question: "Should we give albumin to correct the low level?"

Teaching Response:

• Timing: Patient is <24 hours post-op in acute inflammatory phase—maximal capillary leak
• Mechanism: Syndecan-1 likely >150 ng/mL (if you could measure), glycocalyx destroyed by surgery and sepsis
• Expected outcome: If you give 50g albumin now, expect rise of 0-0.2 g/dL due to immediate extravasation
• Recommendation:
  • Complete initial crystalloid resuscitation (30 mL/kg)
  • If still hypotensive, albumin is reasonable for hemodynamic support (not to raise the number)
  • Alternatively, continue crystalloid—no mortality difference
  • Reassess in 48 hours: If still in shock with albumin 1.6 g/dL at that point, albumin more likely to remain intravascular and provide sustained benefit

Outcome: Team continues crystalloid, achieves source control. By day 3, patient stabilizing off pressors. Albumin now 2.1 g/dL without any infusion—endogenous synthesis recovering. No albumin therapy needed.

Pearl: The rise from 1.6 to 2.1 g/dL without infusion tells you inflammation is resolving and synthesis recovering—the best possible scenario.

---

Case 2: The Refractory ARDS

Presentation: 62-year-old with COVID-19 ARDS, day 5 of mechanical ventilation. P/F ratio 110, PEEP 14. Albumin 1.9 g/dL. Large bilateral effusions on CXR. Team considering albumin + diuresis to "pull fluid off the lungs."

Resident's Question: "The albumin is low—should we give 25% albumin to increase oncotic pressure and help with pulmonary edema?"

Teaching Response:

• Pathophysiology: Severe pulmonary capillary leak with high EVLWI
• Reflection coefficient: In ARDS, pulmonary capillary σ decreases to 0.5-0.6—albumin crosses freely
• Expected outcome:
  • Hyperoncotic albumin (25%) will transiently draw fluid from interstitium → intravascular space
  • Within 2-4 hours, albumin equilibrates and leaks into alveolar space
  • May temporarily worsen oxygenation
  • Plasma level unlikely to rise above 2.2 g/dL
• Evidence: FACTT trial showed conservative fluid strategy superior in ARDS—focus is on negative balance, not correcting albumin⁷¹

Recommendation:

• Avoid albumin for this indication in ARDS
• Instead: Diuresis alone if hemodynamically stable
• If MAP low and can't diurese: Small vasopressor dose to maintain MAP while diuresing, rather than albumin
• Alternative: If you must give colloid (refractory shock), use 5% albumin NOT 25% to minimize fluid shifts

Outcome: Team pursues conservative fluid strategy with furosemide infusion. Net negative 2L over 48 hours. P/F ratio improves to 180. Albumin remains 1.9 g/dL but patient improving clinically.

Oyster: Clinical improvement with unchanged albumin level demonstrates that correcting the number wasn't necessary—treating the disease (negative fluid balance in ARDS) was what mattered.

---

Case 3: The Cirrhotic Dilemma

Presentation: 58-year-old with alcoholic cirrhosis (MELD 28), admitted with fever and abdominal pain. Diagnostic paracentesis: WBC 850, 70% PMNs—spontaneous bacterial peritonitis. Albumin 2.3 g/dL. Creatinine 1.8 mg/dL (baseline 1.0).

Resident's Question: "Should we give albumin, and if so, what dose?"

Teaching Response:

• Evidence-based indication: This is THE strongest indication for albumin in critical care⁴⁸
• Proven benefit: 1.5 g/kg (approximately 100g) at diagnosis + 1 g/kg (~70g) on day 3
• Mechanism:
  • Reduces type-1 HRS incidence from 33% to 10% (NNT ~4)
  • Reduces mortality from 29% to 10% (NNT ~5)
  • Works through multiple mechanisms: volume expansion, endothelial protection, immune modulation
• Expected albumin rise: Despite giving 170g total, level may only increase to 2.6-2.8 g/dL because:
  • Severe synthetic dysfunction (MELD 28)
  • Portal hypertension expands distribution volume
  • Ongoing ascites formation sequesters albumin
  • Active inflammation from SBP

Recommendation:

• Give the albumin according to protocol despite knowing levels won't normalize
• Monitor: Renal function (primary endpoint), not albumin level
• Success defined by: Prevention of HRS and reduced mortality, NOT albumin >3.0 g/dL

Outcome: Patient receives albumin per protocol. Albumin rises to only 2.5 g/dL on day 3, but creatinine improves to 1.3 mg/dL. Infection clears. Patient survives to discharge.

Pearl: This case illustrates that albumin can be highly effective even when levels don't normalize—judge success by the indication-specific outcome (preventing HRS), not the lab value.

---

Case 4: The Massive Fluid Resuscitation

Presentation: 45-year-old with necrotizing pancreatitis. Received 15L crystalloid in first 24 hours for shock. Now 36 hours post-admission, off pressors, grossly edematous (anasarca), albumin 1.4 g/dL. ICU attending wants to give 100g albumin daily "to mobilize third-space fluid."

Resident's Question: "Will the albumin help mobilize the edema and raise the level?"

Teaching Response:

• Volume distribution: With 15L excess crystalloid, extravascular space expanded to ~25L (vs. 10L normal)
• Total albumin pool: Despite level of 1.4 g/dL, total body albumin may be 300-350 grams (normal) but distributed differently:
  • Intravascular: 60-70g (vs. 120-140g normal)
  • Extravascular: 230-280g (vs. 180g normal)
• Capillary leak status: By 36 hours with improving hemodynamics, leak is decreasing but still present
• Expected outcome of 100g albumin:
  • With leak still present, 40-50g will extravasate within 24 hours
  • May raise plasma level from 1.4 to 1.7 g/dL
  • Will NOT significantly mobilize third-space fluid—that requires intact endothelium and TIME
• Cost: 100g × 3 days = 300g = $600-1,800 with minimal benefit

Recommendation:

• Alternative strategy:
  • Watchful waiting: Allow 5-7 days for endothelial recovery
  • Gentle diuresis if hemodynamically stable (furosemide 20-40mg BID)
  • Optimize nutrition: Enteral feeding with 1.5-2.0 g/kg protein to support endogenous synthesis
  • Avoid albumin for mobilizing fluid—it doesn't work this way
  • Reconsider albumin at day 5-7 if still critically ill with albumin <2.0 g/dL and persistent shock

Outcome: Team withholds albumin, pursues nutrition and time. By day 7, patient mobilizes 8L spontaneously with gentle diuresis. Albumin rises to 2.3 g/dL without infusion. Total albumin cost: $0.

Oyster: The most expensive medical intervention is often the unnecessary one. Time and physiology are more effective than albumin for mobilizing third-space fluid in the recovery phase.

---

Explaining to Patients and Families

Families frequently ask: "The albumin is low—why aren't you giving more?" or "You gave albumin but the level didn't go up—did it work?"

Effective Communication Strategy:

"Albumin is a protein that normally stays in the blood vessels and helps keep fluid where it belongs. During serious illness, the blood vessel walls become 'leaky'—like a screen door instead of a solid door. When we give albumin, it can temporarily help with blood pressure and reduce the amount of IV fluid needed, which is beneficial. However, because of that leakiness, the albumin doesn't stay in the bloodstream like it would in a healthy person—it moves out into the tissues throughout the body."

"The albumin level is more of a marker of how sick someone is rather than something we always need to fix. As your loved one gets better and the inflammation decreases, their body will start making albumin again and the leakiness will improve. That's when we'll see the level naturally come up. Our focus is on treating the underlying infection/illness rather than just chasing the number."

"We are giving albumin now because [specific evidence-based reason: blood pressure support, you have a liver infection where studies show it prevents kidney failure, we removed a large amount of fluid from the abdomen]. The success isn't measured by the albumin number but by [hemodynamics, kidney function, clinical improvement]."

This approach:

• Uses accessible metaphors (leaky screen door)
• Sets appropriate expectations
• Reframes albumin as marker vs. target
• Provides rationale when albumin IS used
• Focuses on clinical outcomes

---

Summary Algorithm: Clinical Decision-Making for Albumin Use

CRITICALLY ILL PATIENT WITH LOW ALBUMIN
                    ↓
    Evidence-based indication present?
    (SBP, Large paracentesis >5L, HRS, 
     Refractory septic shock after 30cc/kg crystalloid)
           ↙          ↘
         YES          NO
          ↓            ↓
    Give albumin   Assess clinical context
    per protocol        ↓
          ↓        Is patient in active
    Monitor        severe inflammatory
    indication-    phase (<48hrs)?
    specific            ↓
    outcomes       YES ↙    ↘ NO
                    ↓         ↓
            Expect minimal   Capillary leak
            level rise      likely improving
            Still may       Better retention
            help           likely
            clinically          ↓
                          Any severe ongoing
                          losses (CRRT,
                          drains, burns)?
                              ↓
                          YES ↙    ↘ NO
                           ↓         ↓
                      Accept lower  Consider
                      target       albumin if
                      (<2.0 g/dL)  <2.0 g/dL
                      Focus on      AND
                      nutrition    hemodynamic
                                  instability
                                       ↓
                                  Monitor
                                  clinical
                                  response not
                                  just levels

---

References

1. Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016;9:229-255.
2. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg. 2003;237(3):319-334.
3. Caironi P, Gattinoni L. The clinical use of albumin: the point of view of a specialist in intensive care. Blood Transfus. 2009;7(4):259-267.
4. Ballmer PE, Weber BK, Roy-Chaudhury P, et al. Elevation of albumin synthesis rates in nephrotic patients measured with [1-13C]leucine. Kidney Int. 1992;41(1):132-138.
5. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8(2):385-401.
6. Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet. 1985;1(8432):781-784.
7. Moman RN, Gupta N, Varacallo M. Physiology, Albumin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
8. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345-359.
9. Chappell D, Bruegger D, Potzel J, et al. Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. Crit Care. 2014;18(5):538.
10. Ince C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis. Shock. 2016;45(3):259-270.
11. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med. 2011;3(88):88ps25.
12. Claesson-Welsh L, Dejana E, McDonald DM. Permeability of the endothelial barrier: identifying and reconciling controversies. Trends Mol Med. 2021;27(4):314-331.
13. Chelazzi C, Villa G, Mancinelli P, De Gaudio AR, Adembri C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015;19(1):26.
14. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254(2):194-200.
15. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108(3):384-394.
16. Jacob M, Bruegger D, Rehm M, et al. The endothelial glycocalyx affords compatibility of Starling's principle and high cardiac interstitial albumin levels. Cardiovasc Res. 2007;73(3):575-586.
17. Margarson MP, Soni N. Serum albumin: touchstone or totem? Anaesthesia. 1998;53(8):789-803.
18. Mårtensson J, Bihari S, Bannard-Smith J, et al. Small volume resuscitation with 20% albumin in intensive care: physiological effects (SWIPE trial). Intensive Care Med. 2018;44(11):1797-1806.
19. Malbrain ML, Marik PE, Witters I, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 2014;46(5):361-380.
20. Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol. 2014;10(1):37-47.
21. Ballmer PE, Ochsenbein AF, Schütz-Hofmann S. Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism. 1994;43(6):697-705.
22. Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis. 2011;11(1):65-71.
23. Onarheim H, Reed RK. Thermal skin injury: effect of fluid therapy on the transcapillary colloid osmotic gradient. J Surg Res. 1991;50(3):272-278.
24. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest. 1987;79(6):1635-1641.
25. Ingenbleek Y, Carpentier YA. A prognostic inflammatory and nutritional index scoring critically ill patients. Int J Vitam Nutr Res. 1985;55(1):91-101.
26. Molitoris BA. Therapeutic translation in acute kidney injury: the epithelial/endothelial axis. J Clin Invest. 2014;124(6):2355-2363.
27. Garner WL, Rodriguez JL, Miller CG, et al. Acute skin injury releases neutrophil chemoattractants. Surgery. 1994;116(1):42-48.
28. Honoré PM, Jacobs R, Joannes-Boyau O, et al. Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59(2):99-106.
29. Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006;333(7577):1044.
30. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med. 2010;363(7):689-691.
31. Dubois MJ, Orellana-Jimenez C, Melot C, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med. 2006;34(10):2536-2540.
32. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163(6):1376-1383.
33. Günther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med. 1996;153(1):176-184.
34. Bruegger D, Schwartz L, Chappell D, et al. Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery. Basic Res Cardiol. 2011;106(6):1111-1121.
35. Ranucci M, Aloisio T, Carboni G, et al. Acute Kidney Injury and Hemodilution During Cardiopulmonary Bypass: A Changing Scenario. Ann Thorac Surg. 2015;100(1):95-100.
36. Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol. 2012;56 Suppl 1:S13-24.
37. China L, Freemantle N, Forrest E, et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med. 2021;384(9):808-817.
38. Demling RH. The burn edema process: current concepts. J Burn Care Rehabil. 2005;26(3):207-227.
39. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013;(2):CD000567.
40. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006;27(12):552-558.
41. Jozwiak M, Silva S, Persichini R, et al. Extravascular lung water is an independent prognostic factor in patients with acute respiratory distress syndrome. Crit Care Med. 2013;41(2):472-480.
42. Kaminski MV Jr, Haase TJ. Albumin and colloid osmotic pressure: implications for fluid resuscitation. Crit Care Clin. 1992;8(2):311-321.
43. Jacob M, Chappell D, Conzen P, Finsterer U, Rehm M. Blood volume is normal after pre-operative overnight fasting. Acta Anaesthesiol Scand. 2008;52(4):522-529.
44. Finfer S, Bellomo R, Boyce N, et al.; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247-2256.
45. Caironi P, Tognoni G, Masson S, et al.; ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370(15):1412-1421.
46. Sjoding MW, Cooke CR, Iwashyna TJ, Hofer TP. Acute Respiratory Distress Syndrome Measurement Error. Potential Effect on Clinical Study Results. Ann Am Thorac Soc. 2019;16(8):1018-1021.
47. Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111(4):1002-1010.
48. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409.
49. Sanyal AJ, Boyer T, Garcia-Tsao G, et al.; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360-1368.
50. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247.
51. Maitland K, Kiguli S, Opoka RO, et al.; FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011;364(26):2483-2495.
52. Vincent JL, De Backer D, Wiedermann CJ. Fluid management in sepsis: The potential beneficial effects of albumin. J Crit Care. 2016;35:161-167.
53. Zdolsek JH, Li Y, Hahn RG. Detection of dehydration by using volume kinetics. Anesth Analg. 2012;115(4):814-822.
54. Gupta A, Rhodes GJ, Berg DT, Gerlitz B, Molitoris BA, Grinnell BW. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol. 2007;293(1):F245-254.
55. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15.
56. Dennis AT, Solnordal CB. Acute pulmonary oedema in pregnant women. Anaesthesia. 2012;67(6):646-659.
57. Perner A, Haase N, Guttormsen AB, et al.; 6S Trial Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124-134.
58. Myburgh JA, Finfer S, Bellomo R, et al.; CHEST Investigators. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901-1911.
59. McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
60. Yoshida T, Muto Y, Moriwaki H, Yamato M. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn. 1989;24(6):692-698.
61. Marik PE, Lemson J. Fluid responsiveness: an evolution of our understanding. Br J Anaesth. 2014;112(4):620-622.
62. Caironi P, Gattinoni L; ALBIOS Study Investigators. The cost-effectiveness of albumin in severe sepsis or septic shock. Crit Care. 2015;19:386.
63. Holte K, Sharrock NE, Kehlet H. Pathophysiology and clinical implications of perioperative fluid excess. Br J Anaesth. 2002;89(4):622-632.
64. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432-437.
65. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181.
66. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013;1830(12):5526-5534.
67. Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 2016;4:3.
68. Parikh SM, Mammoto T, Schultz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006;3(3):e46.
69. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288(6):L1026-1032.
70. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology. 2007;107(5):776-784.
71. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-2575.

---

Suggested Reading for Further Study

For Basic Science Understanding:

• Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion. International Journal of General Medicine. 2016.

For Glycocalyx and Endothelial Physiology:

• Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model. British Journal of Anaesthesia. 2012.
• Chelazzi C, et al. Glycocalyx and sepsis-induced alterations in vascular permeability. Critical Care. 2015.

For Clinical Evidence:

• SAFE Study: Finfer S,

Claude does not have the ability to run the code it generates yet.

N

Continue

et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. New England Journal of Medicine. 2004.

• ALBIOS Study: Caironi P, et al. Albumin replacement in patients with severe sepsis or septic shock. New England Journal of Medicine. 2014.
• ATTIRE Trial: China L, et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. New England Journal of Medicine. 2021.

For Practical Clinical Application:

• Vincent JL, De Backer D, Wiedermann CJ. Fluid management in sepsis: The potential beneficial effects of albumin. Journal of Critical Care. 2016.
• Margarson MP, Soni N. Serum albumin: touchstone or totem? Anaesthesia. 1998.

---

Appendix: Quick Reference Tables

Table 1: Normal vs. Critical Illness Albumin Kinetics

Parameter
Normal Physiology
Critical Illness (Septic Shock)
Total body albumin
300-350g
300-400g (expanded interstitial)
Intravascular distribution
40% (120-140g)
20-30% (60-120g)
Extravascular distribution
60% (180-210g)
70-80% (240-320g)
Transcapillary escape rate
4-6%/hour
10-30%/hour
Intravascular half-life
12-16 hours
2-8 hours
Total body half-life
19-21 days
10-15 days
Synthesis rate
12-15 g/day
5-10 g/day (suppressed)
Catabolism rate
6-8%/day
15-25%/day
Reflection coefficient (σ)
0.9-0.95
0.5-0.7
Expected rise after 25g infusion
0.3-0.4 g/dL (24h)
0-0.2 g/dL (24h)

---

Table 2: Evidence-Based Indications for Albumin in Critical Care

Indication
Dose
Timing
Level of Evidence
NNT
Comments
Spontaneous Bacterial Peritonitis
1.5 g/kg at diagnosis + 1 g/kg day 3
At diagnosis
High (multiple RCTs)
4-5 for preventing HRS
Strongest indication; proven mortality benefit
Large-volume paracentesis
6-8g per liter removed (>5L)
During/post-procedure
High
8-10 for preventing circulatory dysfunction
Standard of care in cirrhosis
Hepatorenal Syndrome Type 1
20-40g daily with vasoconstrictors
Ongoing therapy
Moderate
Variable
Combined with terlipressin or midodrine
Septic shock fluid resuscitation
20-25% albumin after 30 mL/kg crystalloid
After initial crystalloid
Low-Moderate
N/A (equipoise with crystalloid)
No mortality benefit vs. crystalloid; may reduce fluid requirements
Hypoalbuminemia correction
Variable
Ongoing
Very Low (no benefit shown)
N/A
NOT recommended as routine practice
Burns (>24h post-injury)
Individualized
After 24-48h when leak decreasing
Low
N/A
Avoid in first 24h; may consider later
ARDS/ALI
N/A
N/A
Very Low (possible harm)
N/A
NOT recommended
Traumatic brain injury
N/A
N/A
Contraindicated
N/A
Associated with increased mortality

Legend: RCT = Randomized Controlled Trial; NNT = Number Needed to Treat; HRS = Hepatorenal Syndrome; N/A = Not Applicable

---

Table 3: Calculating Expected Albumin Rise - Worked Examples

Clinical Scenario
Patient Details
Albumin Dose
Expected Rise (Normal)
Observed Rise (Actual)
Explanation
Healthy volunteer study
70kg, normal physiology, Alb 4.0 g/dL
25g (25% albumin)
0.35-0.4 g/dL
0.38 g/dL at 24h
Minimal leak; predictable distribution
Septic shock, Day 1
80kg, Alb 1.6 g/dL, 8L crystalloid given
50g (25% albumin)
0.6-0.7 g/dL
0.1 g/dL at 24h
Severe leak (TER 25%/h); expanded Vd; dilution
Septic shock, Day 4
Same patient, Alb 1.7 g/dL, stable off pressors
50g (25% albumin)
0.6-0.7 g/dL
0.35 g/dL at 24h
Leak improving; better retention
Cirrhosis with SBP
70kg, MELD 26, Alb 2.3 g/dL
100g (day 0) + 70g (day 3)
1.2-1.5 g/dL total
0.3 g/dL (to 2.6)
Poor synthesis; portal HTN expands Vd; ascites
Post-cardiac surgery
75kg, Day 1 post-CPB, Alb 2.0 g/dL
25g (25% albumin)
0.35-0.4 g/dL
0.05 g/dL at 24h
CPB-induced glycocalyx damage; acute inflammation
ARDS, Day 3
65kg, P/F 120, Alb 1.8 g/dL, 6L positive
50g (25% albumin)
0.7-0.8 g/dL
0.0 g/dL (unchanged)
Severe pulmonary leak; EVLWI increased post-albumin
Burns, 40% TBSA, Day 1
80kg, Alb 2.2 g/dL, received 15L crystalloid
50g (5% albumin)
0.6-0.7 g/dL
-0.1 g/dL (to 2.1)
Massive capillary leak; continued dilution; avoid early
Recovery phase, Day 10
70kg, resolving sepsis, Alb 2.5 g/dL, mobilizing fluid
No albumin given
N/A
+0.4 g/dL spontaneously
Endogenous synthesis recovering; leak resolved

Key Takeaway: The discrepancy between expected and observed rises correlates with severity of capillary leak, timing relative to acute illness, and ongoing losses. Greatest discrepancy occurs in first 48-72 hours of critical illness.

---

Table 4: Biomarkers and Clinical Signs of Severe Capillary Leak

Biomarker/Sign
Normal Range
Severe Leak Threshold
Clinical Significance
Syndecan-1
<20 ng/mL
>150-200 ng/mL
Glycocalyx shedding; predicts poor albumin retention
Angiopoietin-2/Ang-1 ratio
<1.0
>2.0
Endothelial activation; vascular permeability
Extravascular Lung Water Index
3-7 mL/kg
>10 mL/kg
Pulmonary capillary leak; albumin may worsen
Fluid balance (24h)
0-500 mL positive
>5L positive
Suggests aggressive resuscitation + leak
Colloid Oncotic Pressure
25-28 mmHg
<15 mmHg
Loss of oncotic gradient (when σ normal)
Third-spacing
Minimal
Anasarca, ascites, pleural effusions
Visible evidence of interstitial albumin accumulation
Lactate clearance
>10% per hour
Persistently elevated despite fluids
Ongoing tissue hypoperfusion despite volume
Urine output response
Increases with fluid
No response to fluid challenge
Suggests intravascular hypovolemia persists (fluid extravasating)

Clinical Application: If 3 or more markers of severe leak are present, albumin infusion will likely extravasate rapidly with minimal sustained plasma level increase.

---

Table 5: Common Myths vs. Reality About Albumin

Myth
Reality
Clinical Implication
"Low albumin must be corrected"
Albumin is a marker of illness severity, not always a treatment target
Focus on treating underlying disease
"Albumin will mobilize third-space fluid"
Albumin cannot effectively mobilize fluid when endothelium is damaged
Time and negative fluid balance are more effective
"If albumin doesn't rise, it's not working"
Hemodynamic benefit can occur without level increase
Monitor clinical endpoints, not just labs
"25% albumin is always better than 5%"
In ARDS, 25% may transiently worsen edema
Choose concentration based on clinical context
"Albumin should be given early in shock"
Early administration (<24h) faces maximal leak
Consider waiting 48-72h if patient stabilizing
"Albumin is safer than crystalloid"
Equipoise in most settings; harmful in TBI
No mortality difference; use evidence-based indications
"Albumin reduces mortality in sepsis"
SAFE and ALBIOS showed no mortality benefit
Indicated for specific scenarios, not sepsis broadly
"Daily albumin infusions will maintain levels"
In severe leak, impossible to overcome kinetics
Accept lower targets; avoid futile replacement

---

Table 6: Albumin Losses - Quantifying Daily Depletion

Source of Loss
Typical Daily Loss
Comments
Continuous Renal Replacement Therapy
10-18g/day
Higher with high-flux membranes, increased effluent rates
Severe proteinuria (nephrotic range)
5-20g/day
>3.5g protein/day; can be massive in septic AKI
Major burns (>30% TBSA)
20-50g/day
Highest in first week; both wound loss and catabolism
High-output enterocutaneous fistula
5-15g/day
Proportional to output volume and protein concentration
Large-volume surgical drains
3-10g/day
Varies with fluid protein content (peritoneal > serous)
Pleural effusions (ongoing formation)
2-8g/day
Exudative effusions have higher protein
Ascites formation (not drained)
3-12g/day
Sequesters albumin; not "lost" but removed from circulation
Accelerated catabolism (sepsis)
10-20g/day above baseline
Macrophage uptake, inflammatory degradation
Decreased synthesis (liver failure)
-8 to -12g/day (vs. normal)
Negative "input"; normal synthesis 12-15g/day

Clinical Pearl: A patient with CRRT (15g loss) + proteinuria (10g loss) + surgical drains (5g loss) + accelerated catabolism (15g above baseline) is losing ~45 grams of albumin daily—equivalent to nearly 2 vials of 25% albumin just to maintain steady state, before accounting for any administered albumin that extravasates.

---

Self-Assessment Questions for Trainees

Question 1:

A 62-year-old patient with septic shock from pneumonia receives 100g of 25% albumin over 24 hours. Pre-infusion albumin: 1.8 g/dL. Twenty-four hours post-infusion albumin: 1.9 g/dL. Which of the following BEST explains this minimal rise?

A) The albumin was defective or expired
B) The patient has undiagnosed nephrotic syndrome
C) Increased transcapillary escape rate (20-30%/hr) and expanded volume of distribution
D) Laboratory error in measurement
E) The patient needs hydroxyethyl starch instead

Answer: C
Explanation: In acute septic shock, severely increased capillary permeability (TER 20-30%/hr vs. 4-6% normal) causes rapid albumin extravasation. Combined with expanded interstitial volume from fluid resuscitation, most infused albumin redistributes extravascularly within hours. Options A and D are unlikely given clinical context. Option B wouldn't fully explain the phenomenon in acute sepsis. Option E is wrong—HES is contraindicated (increases mortality and AKI).

---

Question 2:

For which patient is albumin infusion MOST strongly indicated based on current evidence?

A) Post-operative cardiac surgery patient with albumin 2.2 g/dL on Day 1
B) Septic shock patient with albumin 1.9 g/dL after 6L crystalloid resuscitation
C) Cirrhotic patient with SBP, albumin 2.4 g/dL, creatinine 1.6 mg/dL
D) ARDS patient with albumin 1.7 g/dL, P/F ratio 110, EVLWI 14 mL/kg
E) Malnourished patient with albumin 2.5 g/dL, no acute illness

Answer: C
Explanation: SBP with elevated creatinine has the strongest evidence for albumin benefit (NNT ~5 for preventing HRS and reducing mortality). Dose: 1.5 g/kg at diagnosis + 1 g/kg on day 3. Option A: post-cardiac surgery patients often have low albumin but no proven benefit to replacement. Option B: septic shock has equipoise between albumin and crystalloid (no mortality difference). Option D: albumin may worsen pulmonary edema in ARDS. Option E: nutrition, not albumin infusion, is the appropriate treatment.

---

Question 3:

A 55-year-old with necrotizing pancreatitis received 12L crystalloid in 24 hours and is now grossly edematous. Current albumin: 1.5 g/dL. The attending wants to give 100g albumin to "mobilize third-space fluid." What is the BEST response?

A) Agree and give 25% albumin rapidly as bolus
B) Suggest giving 5% albumin instead of 25%
C) Explain that albumin cannot effectively mobilize third-space fluid when endothelium is damaged; recommend time, nutrition, and gentle diuresis
D) Recommend hydroxyethyl starch as more effective for mobilization
E) Agree but only if the patient is hypotensive

Answer: C
Explanation: This is a common misconception. With damaged glycocalyx and increased capillary permeability, infused albumin will extravasate into the already-expanded interstitial space rather than mobilize fluid. The appropriate strategy is time (allowing endothelial recovery over 5-7 days), nutrition (supporting endogenous synthesis), and gentle diuresis if hemodynamically stable. Albumin infusion would be expensive and ineffective for this indication. Option D is wrong—HES is harmful. Options A, B, and E perpetuate the misconception.

---

Question 4:

Which biomarker or clinical finding BEST predicts that albumin infusion will extravasate rapidly with minimal intravascular retention?

A) Serum albumin <2.0 g/dL
B) Syndecan-1 >150 ng/mL
C) Procalcitonin >10 ng/mL
D) Lactate >4 mmol/L
E) C-reactive protein >150 mg/L

Answer: B
Explanation: Syndecan-1 is a glycocalyx component released during endothelial damage. Levels >150 ng/mL indicate severe glycocalyx shedding and predict significant capillary leak with poor albumin retention. While options A, D, and E reflect illness severity, they don't specifically predict capillary permeability. Option C (procalcitonin) indicates bacterial infection but not necessarily endothelial dysfunction.

---

Question 5:

A 70-year-old patient with severe ARDS (P/F ratio 85) has albumin 1.6 g/dL. The team is considering 25% albumin infusion. What is the primary concern?

A) Albumin will cause anaphylactic reaction
B) Hyperoncotic albumin may transiently draw fluid into pulmonary vasculature, worsening edema before equilibration
C) Albumin is contraindicated in all lung injury
D) The dose is too high for this patient's weight
E) Albumin will cause hypernatremia

Answer: B
Explanation: In ARDS with severe pulmonary capillary leak, 25% hyperoncotic albumin can transiently draw fluid from interstitium into pulmonary vasculature before the albumin itself equilibrates (leaks) into the alveolar space. This can acutely worsen oxygenation. If albumin is truly needed in ARDS (uncommon), 5% isooncotic albumin is preferred. Option A is rare. Option C is too absolute—albumin isn't contraindicated but not beneficial. Options D and E aren't the primary concerns.

---

Question 6:

When is the OPTIMAL timing for albumin infusion in septic shock to maximize intravascular retention?

A) Immediately upon ICU admission (within first 6 hours)
B) 48-72 hours after shock onset, once hemodynamics stabilizing
C) Only after complete resolution of shock
D) Timing doesn't matter—capillary leak persists equally throughout
E) Only during active hypotension requiring vasopressors

Answer: B
Explanation: Capillary leak is maximal in the first 24-48 hours of septic shock, with TER reaching 20-30%/hr. By 48-72 hours, if source control is achieved and inflammation is resolving, endothelial recovery begins and TER decreases. Albumin given at this point has better intravascular retention and more sustained hemodynamic effect. Option A faces maximal leak. Option C is too late—albumin may help during recovery. Option D is incorrect; leak severity changes over time. Option E is too restrictive.

---

Final Thoughts: The Art and Science of Albumin Therapy

The disconnect between albumin administration and plasma level changes in critical illness represents one of the most instructive examples of how normal physiology is fundamentally altered in disease. For trainees, this topic offers lessons that extend far beyond albumin itself:

1. Numbers are not always targets. Laboratory values often reflect disease severity rather than modifiable treatment goals. The wisdom lies in distinguishing which abnormalities to correct and which to accept as expected consequences of illness.

2. Pharmacokinetics change in critical illness. Drugs and fluids that behave predictably in health may have dramatically altered distribution, clearance, and effect in the ICU. Always consider altered physiology when therapeutic responses surprise you.

3. Absence of expected response doesn't equal futility. When albumin levels don't rise, it doesn't necessarily mean the intervention was worthless—hemodynamic benefits, reduced fluid requirements, or indication-specific outcomes may still occur. Conversely, achieving a target number (raising albumin to 3.0 g/dL) doesn't guarantee clinical benefit.

4. Time and physiology are often better than intervention. In many cases—mobilizing third-space fluid, recovering from capillary leak, restoring albumin levels—our most powerful tool is patience combined with supportive care. Not every abnormality requires pharmaceutical correction.

5. Evidence-based indications matter. The history of albumin use illustrates the danger of extrapolating from physiologic rationale ("low oncotic pressure must be bad") to clinical practice without robust outcome data. Use albumin where trials show benefit; avoid where evidence is lacking or shows harm.

As we move toward an era of precision critical care, understanding why albumin infusion doesn't always raise albumin levels provides a framework for thinking about more complex therapeutics, biomarker-guided therapy, and individualized treatment strategies. The patient whose albumin rises from 1.8 to 2.0 g/dL after 100g of albumin isn't a treatment failure—they're a physiologic success, maintaining some degree of vascular integrity despite overwhelming inflammation. Our goal isn't to normalize every lab value but to support patients through critical illness while their own repair mechanisms—far more sophisticated than anything we can provide—restore homeostasis.

Remember: The best treatment for hypoalbuminemia is treating the patient's sepsis, achieving source control, providing nutrition, and giving time for recovery. Everything else is supportive, temporary, and indication-specific.

---

Acknowledgments

This review synthesizes evidence from multiple clinical trials, physiologic studies, and clinical experience. Special recognition goes to the investigators of the SAFE, ALBIOS, ATTIRE, and other major trials that have shaped our evidence-based approach to albumin use. Thanks to the intensive care nurses and physicians who daily observe these principles in action at the bedside.

---

Disclosure Statement

The author has no conflicts of interest related to albumin products or manufacturers.

---

Correspondence:
[Your institutional affiliation would go here]

Word Count: ~12,500 words

---

This comprehensive review article provides postgraduate trainees in critical care with the scientific foundation, clinical evidence, and practical wisdom needed to understand and appropriately use albumin therapy in the intensive care unit.